At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,021 enrolled
Drug / intervention
Rasagilinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
AZILECT Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"
In Brief
An observational study evaluating Rasagiline for Parkinson's Disease. Completed, enrolled 1,021 participants across 1 site.
Detailed Summary
The purpose of this survey is to evaluate the long-term safety of Rasagiline (AZILECT) in patients with Parkinson's disease in daily clinical practice and also collect efficacy information.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartNov 2018
Primary CompletionOct 2021
TodayJul 2026
First PostedNov 1, 2018
Enrollment StartNov 1, 2018
Primary CompletionOct 31, 2021
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 7.7 years ago
Interventions
Rasagilinedrug
Rasagiline Tablets